The number of people with HIV is still very high, but the condition is no longer the death sentence it used to be not too long ago. Today, there are more than 34 million people living with HIV/AIDS around the world, and an estimated 7,000 people still contract the disease every day. The HIV drug market is still very lucrative, and as long as daily therapies are part of the treatment, it’ll continue to generate a steady stream of revenue for pharmaceutical companies.
According to Frost & Sullivan, the European HIV drug market earned $5.58 billion in 2012, and estimates it will grow to $9.24 billion by 2019.
The new report from Frost & Sullivan, titled “Analysis of the European HIV Drugs Market,” is projecting the release of oral combination pills currently in the pipeline will have a significant impact on the European HIV drug market.
The analysis provides insights into the most widely used antiretroviral (ARV) therapies, including: nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitors, and other therapeutics (ARV compounds like CCR5 receptor antagonists, fusion inhibitors, maturation inhibitors, attachment inhibitors and PK boosters).
Research is made from the point of view of the manufacturer, with segmentation by drug classes and major Western European countries.
"In addition to popularly existing therapies like NRTI, NNRTI, PI and integrase inhibitors, new drug candidates over the last decade have spurred the HIV drugs market. The development of new candidates, derived from the less commonly used types of ARV therapies like PK boosters, maturation inhibitors, and attachment inhibitors, is driving the overall market," said Frost & Sullivan Healthcare Research Analyst, Deepika Pramod Chopda.
HIV is a condition that can be prevented in the vast majority of the cases. Government bodies and private organizations around the world are emphasizing the importance of awareness in further eradicating this disease.
While the number of cases has dramatically decreased worldwide, developing countries with limited access to accurate information still have higher rates of HIV.
Edited by
Braden Becker
